Loading clinical trials...

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation | Clinical Trials | Clareo Health

COMPLETED

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)

NCT03873857•AbbVie

View on ClinicalTrials.gov

Summary

This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in the Russian Federation.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has a confirmed diagnosis of relapsed or refractory CLL.
•Patient for whom the physician has decided to initiate CLL treatment with venetoclax (mono and combo therapy), or up to 4 weeks after venetoclax treatment initiation
•Patient voluntarily agrees to participate in this study and signs informed consent form

Exclusion Criteria

•Has contraindications to venetoclax as listed on the approved local label in Russian Federation.
•Has Richter syndrome
•Participated in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation

Locations (20)

Oncology Dispensary #2 /ID# 215831

Sochi, Krasnodarskiy Kray, Russia

Moscow State budget healthcare /ID# 212875

Moscow, Moscow, Russia

Moscow Regional Research and Clinical Institute n.a. Vladimirskiy (MONIKI) /ID# 215830

Moscow, Moscow Oblast, Russia

Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 212368

Saint Petersburg, Sankt-Peterburg, Russia

Central City Hospital #7 /ID# 212373

Yekaterinburg, Sverdlovsk Oblast, Russia

Regional Children's Clinical Hospital of Volgograd /ID# 212366

Volgograd, Volgograd Oblast, Russia

Krai Clinical Hospital /ID# 224952

Barnaul, Russia

GBUZ Regional Cancer center /ID# 216871

Irkutsk, Russia

Krai Clinical Hospital #1 /ID# 212367

Khabarovsk, Russia

Kirov Regional Clinical Hospital /ID# 217579

Kirov, Russia

Key Dates

Start Date

February 25, 2019

Primary Completion Date

September 12, 2022

Completion Date

September 12, 2022

Last Updated

September 1, 2023

Enrollment

ACTUAL participants

Conditions

Chronic Lymphocytic Leukemia (CLL)Cancer

Interventions

Venetoclax

DRUG

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGEARLY_PHASE1

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398

Skin CancerKidney Transplant Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)